Varicella-Zoster Virus glycoprotein E and Influenza virus hemagglutinin (VZV gE and Influenza HA)

The target entry Immune system via VZV gE and influenza hemagglutinin antigens refers to a vaccine strategy targeting the human immune system using two distinct viral antigens: Varicella-Zoster Virus (VZV) glycoprotein E and Influenza virus hemagglutinin (HA). VZV glycoprotein E is the most abundant surface protein of the shingles virus and is essential for viral cell-to-cell spread and skin infection (UniProt: P09333). Influenza hemagglutinin is a class I fusion protein that mediates viral attachment to sialic acid receptors on host cells, facilitating viral entry (NCBI: Influenza). In therapeutic development, these antigens are often combined in mRNA-based vaccine platforms to elicit robust humoral and cellular immune responses against both Herpes zoster and seasonal influenza (Pfizer, 2023). This combination approach aims to streamline immunization schedules for older adults who are at high risk for both diseases.

Other names

VZV gEInfluenza HAVaricella-Zoster Virus glycoprotein EHemagglutininShingles and Flu vaccine antigens

Active immunization via induction of neutralizing antibodies and T-cell responses against VZV gE and Influenza HA antigens (PubMed: PMC7120343).